News from the University of Chicago
Engineered immune cells could give doctors new precision when fighting tumors.
Researchers at the University of Chicago have developed a modular cancer immunotherapy that can be switched on, off or reprogramed to attack different cancers.
Promising initial testing results, published in Science Advances, demonstrate a “universal” function built on a chimeric antigen receptor (CAR) platform. This could make immunotherapy safer and easier to adapt to each patient—dramatically changing the treatment landscape for certain cancers.
Full story: New ‘plug-and-play’